Protocol Ledger

NCT05153239 · Phase III · COMPLETED

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Interventional Phase III clinical trial protocol NCT05153239 sponsored by PharmaMar in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-22 Enrollment: 705 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05153239
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)705 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05153239
Protocol FieldVerified Registry Value
NCT IdentifierNCT05153239
Consolidated Lead SponsorPharmaMar
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment705 participants (ACTUAL)
Registered Start Date2022-07-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI